3-氨基-1-萘甲酸 | 32018-86-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 3-氨基-1-萘甲酸
• 英文名称: 3-aminonaphthalene-1-carboxylic acid
• 英文别名: 3-Amino-1-naphthoic acid；3-amino-1-napthalenecarboxylic acid；3-amino-[1]naphthoic acid；3-Amino-[1]naphthoesaeure；3-amino-1-naphthalenecarboxylic acid
• CAS: 32018-86-3
• 化学式: C₁₁H₉NO₂
• mdl: MFCD13180528
• 分子量: 187.198
• InChiKey: YIPRQTYMJYGRER-UHFFFAOYSA-N

物化性质

• 熔点：
  179 °C
• 沸点：
  456.1±28.0 °C(Predicted)
• 密度：
  1.352±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  3-氨基-1-萘甲酸 在 硫酸 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 1.75h， 生成 3-羟基-1-萘酸
  参考文献：
  名称：

  Thrombopoietin mimetics

  摘要：

  非肽TPO类似物已经被揭示，以及一种治疗血小板减少症的方法，在需要的哺乳动物中，包括人类，在这种哺乳动物中给予选择的羟基-1-偶氮萘衍生物的有效量。

  公开号：

  US06670387B1
• 作为产物：
  描述：

  3-硝基-1-萘甲酸 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 以3.2 g的产率得到3-氨基-1-萘甲酸
  参考文献：
  名称：

  Dissociation of Naphthoic Acids in Non-Aqueous Media. Comparison of Benzene and Naphthalene Skeletons

  摘要：

  通过新的或修改过的程序合成了七种单取代的1-萘甲酸，并在25°C下在甲醇、乙腈、二甲基甲酰胺和吡啶中用电位法测量了它们的离解常数。这些单取代的1-萘甲酸与之前研究的十三种取代的1-萘甲酸和二十五种取代的2-萘甲酸的离解常数在25°C下在乙醇和二甲基亚砜中进行了测量。3-和4-取代的1-萘甲酸的pK_HA值通过简单线性回归和主成分分析进行处理，并将结果用于比较模型化合物以及目的是比较苯和萘骨架的相应3-和4-取代苯甲酸。研究发现，1-萘基系统的3位和4位可以分别与苯的间位和对位进行粗略比较。

  DOI：

  10.1135/cccc20000385

文献信息

• [EN] PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES<br/>[FR] COMPOSES PYRROLIQUES DESTINES AU TRAITEMENT DE MALADIES INDUITES PAR PROSTAGLANDINE
  申请人：GLAXO GROUP LTD

  公开号：WO2003101959A1

  公开（公告）日：2003-12-11

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, R1, R2a, R2b, Rx, R8, and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine, in particular their use in the treatment of prostaglandin mediated diseases such as pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

  式(I)的化合物或其药学上可接受的衍生物：其中A、R1、R2a、R2b、Rx、R8和R9如规范中所定义，一种制备这种化合物的方法，包括这种化合物的药物组合物以及这种化合物在医学中的用途，特别是它们在治疗前列腺素介导的疾病，如疼痛、炎症、免疫、骨骼、神经退行性或肾脏疾病中的用途。
• NOVEL TETRACARBOXYLIC DIANHYDRIDE, POLYIMIDE RESIN AND METHOD FOR PRODUCING THE SAME, PHOTOSENSITIVE RESIN COMPOSITIONS, PATTERNING PROCESS, METHOD FOR FORMING CURED FILM, INTERLAYER INSULATING FILM, SURFACE PROTECTIVE FILM, AND ELECTRONIC PARTS
  申请人：SHIN-ETSU CHEMICAL CO., LTD.

  公开号：US20190169211A1

  公开（公告）日：2019-06-06

  The present invention has been made in view of the circumstances herein. An object of the present invention is to provide: a tetracarboxylic dianhydride which can lead to a polyimide usable as a base resin of a photosensitive resin composition capable of forming a fine pattern and obtaining high resolution without impairing excellent characteristics such as mechanical strength and adhesiveness; a polyimide resin obtained by using the tetracarboxylic dianhydride; and a method for producing the polyimide resin. The tetracarboxylic dianhydride is shown by the following general formula (1).

  本发明是基于本文中的情况而作出的。本发明的目的是提供：一种四羧酸二酐，可导致聚酰亚胺，作为感光树脂组合物的基树脂，能够形成细微图案并获得高分辨率，同时不损害优异的特性，如机械强度和粘附性；通过使用该四羧酸二酐获得的聚酰亚胺树脂；以及生产该聚酰亚胺树脂的方法。该四羧酸二酐由以下通用式（1）所示。
• [EN] CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS MACROCYCLIQUES ENTIÈREMENT SYNTHÉTIQUES, À CONFORMATION CONTRAINTE
  申请人：POLYPHOR AG

  公开号：WO2011015241A1

  公开（公告）日：2011-02-10

  Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of type (I) are constituted by three distinct building blocks: an aromatic template a, a conformation modulator b and a spacer moiety c as detailed in the description and the claims. Macrocycles of type (I) are readily manufactured by parallel synthesis or combinatorial chemistry. They are designed to interact with specific biological targets. In particular, they show agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT2B (5-HT2B receptor), and on the prostaglandin F2 • receptor (FP receptor). They are thus potentially useful for the treatment of hypomotility disorders of the gastrointestinal tract such as diabetic gastroparesis and constipation type irritable bowl syndrome; of CNS related diseases like migraine, schizophrenia, psychosis or depression; of ocular hypertension such as associated with glaucoma and preterm labour.

  构象受限、空间定义的12-30元大环环系统(I型)由三个不同的构建模块组成：芳香模板a、构象调节剂b和间隔基团c，详细描述在说明书和专利要求中。I型大环可通过并行合成或组合化学方法轻松制备。它们设计用于与特定生物靶点相互作用。特别是，它们在胃动素受体(MR受体)、5-羟色胺受体亚型5-HT2B(5-HT2B受体)和前列腺素F2•受体(FP受体)上显示激动或拮抗活性。因此，它们潜在用于治疗胃肠道低动力障碍，如糖尿病性胃轻瘫和便秘型肠易激综合征；中枢神经系统相关疾病，如偏头痛、精神分裂症、精神病或抑郁症；眼压增高，如青光眼和早产。
• CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS
  申请人：Obrecht Daniel

  公开号：US20120270881A1

  公开（公告）日：2012-10-25

  Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of formulae Ia and Ib are constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. These macrocycles Ia and Ib are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being the agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), ion channels and signal transduction pathways. In particular, these macrocycles act as antagonists of the motilin receptor, the FP receptor and the purinergic receptors P2Y 1 , as modulators of the serotonin receptor of subtype 5-HT 2B , as blockers of the voltage-gated potassium channel K v 1.3 and as inhibitors of the β-catenin-dependent “canonical” Wnt pathway. Thus they are showing great potential as medicaments for a variety of diseases.

  具有结构限制的、空间定义的12-30环的大环系统Ia和Ib由三个不同的分子部分构成：模板A、构象调节剂B和桥C。这些大环Ia和Ib可以通过并行合成或溶液中或固相上的组合化学来轻松制备。它们被设计用于与各种特定的生物靶标类相互作用，例如对G蛋白偶联受体（GPCRs）、离子通道和信号转导途径的激动或拮抗活性。特别地，这些大环作为莫蒂林受体的拮抗剂、FP受体和嘌呤受体P2Y1的调节剂、5-HT2B亚型的5-羟色胺受体的调节剂、电压门控钾通道Kv1.3的阻断剂以及β-连环蛋白依赖的“经典”Wnt途径的抑制剂。因此，它们显示出作为各种疾病药物的巨大潜力。
• Antibiotic compounds
  申请人：Zeneca Limited

  公开号：US05571805A1

  公开（公告）日：1996-11-05

  The present invention relates to carbapenems and provides a compound of the formula (I) ##STR1## wherein: R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxyethyl; R.sup.2 is hydrogen or C.sub.1-4 alkyl; R.sup.3 is hydrogen or C.sub.1-4 alkyl; P is of the formula (IA), (IB) or (IC) ##STR2## and in the formula (IB) the naphthyl group may be bonded to the nitrogen of the linking carbamoyl group at either ring; Z is carboxy, sulfonic acid, sulfinic acid, C.sub.1-4 alkanamidosulfonyl (--SO.sub.2 NHCOC.sub.1-3 alkyl), benzamidosulfonyl, C.sub.1-4 alkylsulfonylcarbamoyl (--CONHSO.sub.2 C.sub.1-4 alkyl), phenylsulfonylcarbamoyl, C.sub.1-4 alkoxy carbamoyl, hydroxycarbamoyl, sulfoamino, N--C.sub.1-4 alkanesulfonamido, cyanocarbamoyl, cyanosulfamoyl, tetrazol-5-yl, 3-hydroxyisoxazol-4-yl and 3-hydroxyisoxazol-5-yl; and P is optionally further substituted provided that when P is of the formula (IA) or (IC), Z is not carboxy; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them are also described.

  本发明涉及碳青霉烯类药物，并提供了一种具有以下结构的化合物（I）： 其中：R.sup.1为1-羟基乙基、1-氟乙基或羟基乙基；R.sup.2为氢或C.sub.1-4烷基；R.sup.3为氢或C.sub.1-4烷基；P为以下结构之一（IA）、（IB）或（IC）： 在结构（IB）中，萘基可以与连接的碳酰胺基团的氮原子结合在任一环上；Z为羧基、磺酸、亚磺酸、C.sub.1-4烷基氨基磺酰（-SO.sub.2 NHCOC.sub.1-3烷基）、苯甲酰磺酰、C.sub.1-4烷基磺酰基碳酰胺（-CONHSO.sub.2 C.sub.1-4烷基）、苯基磺酰基碳酰胺、C.sub.1-4烷氧基碳酰胺、羟基碳酰胺、磺酰氨基、N-烷基磺酰氨基、氰基碳酰胺、氰基磺酰胺、四唑-5-基、3-羟基异噁唑-4-基和3-羟基异噁唑-5-基；P可进一步取代，但当P为结构（IA）或（IC）时，Z不为羧基；或其药学上可接受的盐或体内可水解的酯。还描述了其制备方法、制备中间体、作为治疗剂的用途以及含有它们的药物组合物。